title: Identification of rat urinary and biliary metabolites of esonarimod, a novel antirheumatic drug, using liquid chromatography/electrospray ionization tandem mass spectrometry with postcolumn addition of 2-(2-methoxyethoxy)ethanol, a signal-enhancing modifier.
abstract: The biotransformation of esonarimod (KE-298) [(+/-)-2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid], a new antirheumatic drug, was investigated in rats. Urinary and biliary excretions within 24 h after oral administration of 5 mg/kg [(14)C]esonarimod accounted for 89 and 10% of the dose, respectively. Initial metabolite analysis by liquid chromatography/electrospray ionization tandem mass spectrometry with negative ion mode, in which a mobile phase of 20 mM ammonium acetate (pH 4.6)/methanol with gradient-elution mode was used, failed to obtain any structural information on most of the metabolites due to poor sensitivity. To overcome this problem, postcolumn addition of 2-(2-methoxyethoxy)ethanol, a powerful signal-enhancing modifier, to the mobile phase was used, allowing pronounced signal enhancement and structural elucidation of urinary and biliary metabolites. The results of metabolite analysis suggested that esonarimod is predominantly biotransformed to a pharmacologically active metabolite, thiol-containing deacetyl-esonarimod (M-I), and subsequently undergoes extensive metabolism, mainly S-methylation followed by the combination of S-oxidation and oxidative conversion of the aromatic methyl group. No disulfide metabolites, such as M-I-cysteine mixed disulfide and M-I-dimer, were found in the excreta. This finding is probably evidence supporting the notion that the reactivity of the thiol moiety of M-I with macromolecules in vivo is extremely lower than that of common thiol-containing drugs.
authors.affiliation: Drug Metabolism Laboratory, Pharmaceutical Research Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan. s13557@ccm.taisho.co.jp
authors.forename: J
authors.initials: J
authors.lastname: Yamaguchi
authors.forename: M
authors.initials: M
authors.lastname: Ohmichi
authors.forename: M
authors.initials: M
authors.lastname: Hasegawa
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: N
authors.initials: N
authors.lastname: Ogawa
authors.forename: S
authors.initials: S
authors.lastname: Higuchi
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000493:pharmacokinetics* / Q000652:urine; D001646:Bile / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D000431:Ethanol / Q000031:analogs & derivatives* / Q000737:chemistry*; D008297:Male; D010654:Phenylbutyrates; D051381:Rats; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*
chemical_list: C433674:(4-hydroxymethylphenyl)-2-methylthiomethyl-4-oxobutanoic acid; C403469:2-(2-methoxyethoxy)ethanol; D018501:Antirheumatic Agents; D010654:Phenylbutyrates; D000431:Ethanol